Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore.
Memory, Aging and Cognition Centre, National University Health Systems, Kent Ridge, Singapore.
Alzheimers Dement. 2021 Oct;17(10):1649-1662. doi: 10.1002/alz.12332. Epub 2021 Mar 31.
There is increasing evidence that phosphorylated tau (P-tau181) is a specific biomarker for Alzheimer's disease (AD) pathology, but its potential utility in non-White patient cohorts and patients with concomitant cerebrovascular disease (CeVD) is unknown.
Single molecule array (Simoa) measurements of plasma P-tau181, total tau, amyloid beta (Aβ)40 and Aβ42, as well as derived ratios were correlated with neuroimaging modalities indicating brain amyloid (Aβ+), hippocampal atrophy, and CeVD in a Singapore-based cohort of non-cognitively impaired (NCI; n = 43), cognitively impaired no dementia (CIND; n = 91), AD (n = 44), and vascular dementia (VaD; n = 22) subjects.
P-tau181/Aβ42 ratio showed the highest area under the curve (AUC) for Aβ+ (AUC = 0.889) and for discriminating between AD Aβ+ and VaD Aβ- subjects (AUC = 0.903). In addition, P-tau181/Aβ42 ratio was associated with hippocampal atrophy. None of the biomarkers was associated with CeVD.
Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD.
越来越多的证据表明磷酸化 tau（P-tau181）是阿尔茨海默病（AD）病理的特异性生物标志物，但它在非白种人群体和伴有脑血管疾病（CeVD）的患者中的潜在应用尚不清楚。
采用单分子阵列（Simoa）测量血浆 P-tau181、总 tau、淀粉样蛋白β（Aβ）40 和 Aβ42 ，以及衍生比值与神经影像学模式相关，这些模式表明脑淀粉样蛋白（Aβ+）、海马萎缩和 CeVD 在新加坡的非认知障碍（NCI；n=43）、认知障碍但无痴呆（CIND；n=91）、AD（n=44）和血管性痴呆（VaD；n=22）患者队列中。
P-tau181/Aβ42 比值对 Aβ+的曲线下面积（AUC）最高（AUC=0.889），并且在区分 AD Aβ+和 VaD Aβ-患者方面具有最高的 AUC（AUC=0.903）。此外，P-tau181/Aβ42 比值与海马萎缩有关。没有任何生物标志物与 CeVD 相关。
血浆 P-tau181/Aβ42 比值可能是一种非侵入性方法，可用于在伴有 CeVD 的人群中识别具有脑淀粉样蛋白升高的 AD。
